Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of olaparib maintenance therapy in biomarker-positive high-grade ovarian cancer
jRCT2080223978Phase 2Completed
- Sponsor
- The University of Tokyo Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Olaparib maintenance with Placebo control (2 arms). Primary endpoints: Progression-free survival, Hazard ratio versus null hypothesis benchmark and 1 more. Started Jul 2018; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080223978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223978.